The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases.
BacciG., PicciP., FerrariS.. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Cancer.1993; 72: 3227–3238.
2.
BacciG., FerrariS., BertoniF.. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the instituto ortopedico rizzoli according to the instituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol.2000; 18: 4016–4027.
3.
HudsonM., JaffeM.R., JaffeN.. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol.1990; 8: 1988–1997.
4.
BramwellV., BurgersM., SneathR.. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European osteosarcoma intergroup. J Clin Oncol.1992; 10: 1579–1591.
5.
BacciG., RuggieriP., PicciP.. Intraarterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the treatment of osteosarcoma of the extremities. results of a randomized study. J Chemother.1996; 8: 70–81.
6.
FuchsN., BielackS.S., EplerD.. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol.1998; 9: 893–899.
7.
MeyersP.A., SchwartzC.L., KrailoM.. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol.2005; 23: 2004–2011.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24: 2932–2947.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
14.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
15.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
16.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85: 1099–1101.
17.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
18.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
19.
KrisM.G., GrallaR.J., ClarkR.A.. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3: 1379–1384.
20.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–158.
21.
KintzelP.E.Anticancer drug-induced kidney disorders. Drug Saf.2001; 24: 19–38.
22.
PitmanS.W., FreiE3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep.1977; 61: 695–701.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24: 3187–3205.
